scholarly journals Active surveillance for highly resistant microorganisms in patients with prolonged hospitalization

2020 ◽  
Vol 9 (1) ◽  
Author(s):  
Guido J. H. Bastiaens ◽  
Tom Baarslag ◽  
Corinne Pelgrum ◽  
Ellen M. Mascini
Keyword(s):  
Active Surveillance ◽  
Risk Groups ◽  
Nosocomial Transmission ◽  
Hospital Policy ◽  
Prolonged Hospitalization

AbstractWe evaluated a new hospital policy comprising active surveillance for highly resistant microorganisms (HRMO) in patients with prolonged hospitalization, including detection of nosocomial transmission after identification of HRMO carriers. Our findings raise the question of whether active surveillance should be extended from traditional risk groups to patients with prolonged hospitalization.

Expanded criteria in men on active surveillance monitored by MRI-TRUS fusion biopsy.

2016 ◽  
Vol 34 (2_suppl) ◽  
pp. 115-115
Author(s):  
Thomas P Frye ◽  
Steven F. Abboud ◽  
Richard Ho ◽  
Michele Fascelli ◽  
Raju Chelluri ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Active Surveillance ◽  
Progression Free Survival ◽  
Risk Groups ◽  
Low Risk ◽  
Intermediate Risk ◽  
Guided Biopsy ◽  
Risk Prostate Cancer ◽  
Expanded Criteria ◽  
Clinically Significant

115 Background: Active surveillance (AS) is an established option for men with prostate cancer. Studies have shown that multiparametric-MRI along with MRI-TRUS fusion-guided biopsy (FB) may better assess risk in patients eligible for AS, compared to 12-core biopsy, due to improved detection of clinically significant cancers. The objective is to evaluate the performance of expanded criteria eligibility in men on AS being monitored with MRI-TRUS guided biopsy. Methods: Men on AS were included if they had mp-MRI and pathology data for 2 or more FB sessions. FB procedures consisted of targeted biopsies and random 12 core biopsies. Men participated in AS with low and intermediate risk prostate cancer, Gleason score ≤ 3+4=7 with no restriction on percent core involvement or number of cores positive. Progression was defined by patients with initial Gleason 3+3=6 to any Gleason 4, and Gleason 3+4=7 disease progressing to a primary Gleason 4 or higher. Results: 124 men on AS met study criteria. Low risk men had a mean age of 61.3 years versus intermediate risk men with a mean age of 65.5 years (p=0.0062). Mean PSA levels of the low and intermediate risk groups were 5.8 and 5.76 ng/ml (p=0.95), respectively. The mean length of follow-up was 22.56 months (range: 3.6 – 74.4 mo). Rates of pathologic progression in the intermediate and low risk patients were, 38.5% vs. 28.5% (p=0.33). Intermediate risk men had a mean progression-free survival (PFS) of 2.8 years compared to low risk men of 3.9 years (p=0.27). Patients were stratified according to established AS criteria (Epstein, Toronto, PRIAS) and rates of progression are summarized in the Table. 69% of patients met Epstein criteria for AS of which 29.4% (20/68) progressed compared to 28.5% for the low risk cohort overall. Conclusions: Men in our cohort who met strict criteria for AS had the same rate of progression as the entire expaned criteria low risk cohort, 29.4% vs 28.5%, respectively. Our data suggests that with accurate initial Gleason classification other AS criteria such as percent core or number of cores positive have no added benefit in predicting which men may have reclassification or progression of disease. [Table: see text]

scholarly journals Invasive Listeriosis in the Foodborne Diseases Active Surveillance Network (FoodNet), 2004–2009: Further Targeted Prevention Needed for Higher-Risk Groups

2012 ◽  
Vol 54 (suppl_5) ◽  
pp. S396-S404 ◽  
Author(s):  
Benjamin J. Silk ◽  
Kashmira A. Date ◽  
Kelly A. Jackson ◽  
Régis Pouillot ◽  
Kristin G. Holt ◽  
...  
Keyword(s):  
Active Surveillance ◽  
Risk Groups ◽  
Foodborne Diseases ◽  
Targeted Prevention ◽  
Surveillance Network

Conditional progression-free survival in men on active surveillance for prostate cancer stratified by NCCN risk.

2021 ◽  
Vol 39 (6_suppl) ◽  
pp. 222-222
Author(s):  
Andrew Gusev ◽  
Florian Rumpf ◽  
Keyan Salari ◽  
Jeffrey Twum-Ampofo ◽  
Matthew F Wszolek ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Active Surveillance ◽  
Progression Free Survival ◽  
Risk Groups ◽  
Low Risk ◽  
Conditional Survival ◽  
Free Survival ◽  
Kaplan Meier ◽  
Grade Progression

222 Background: Active surveillance (AS) is an accepted management strategy for men with very low, low, and select cases of favorable intermediate National Comprehensive Cancer Network (NCCN) risk prostate cancer (PCa). However, how patients’ risk of disease progression evolves over time during AS has not been well defined. Conditional survival measures the probability a patient will continue to survive some number of years, given that they have already survived a certain number without progression. We evaluated our AS cohort to investigate overall and conditional progression free survival on AS, stratified by the NCCN risk groups. Methods: We reviewed our institutional database of 1254 men enrolled in AS for localized PCa from 1996-2016. Our AS protocol includes prostate specific antigen (PSA) and digital rectal exam (DRE) every 4-6 months for 3 years, then annually. Mandatory confirmatory 12 core biopsy is done at 12-18 months. Multiparametric magnetic resonance imagining (mpMRI) or additional systematic or MRI-fusion biopsies are done at the discretion of physician and patient. Overall freedom from pathologic grade progression on follow-up biopsy and treatment free survival were estimated using the Kaplan-Meier method. Survival curves were compared pairwise using the Log-rank test and adjusted for false discovery rates with the Benjamini-Hochberg procedure. Three-year conditional survival estimates were derived for both outcomes from the Kaplan-Meier estimator. Results: Of 1254 men, 521 (41.6%) met criteria for very low, 606 (48.4%) for low, and 125 (10.0%) for favorable intermediate NCCN risk at diagnosis. Median follow-up time was 6.5 years (IQR 4.1-9.4). Median pathologic grade progression free survival in years was significantly longer for very low risk (7.8, 95% CI 6.8-11.2) compared to low risk men (5.6, 95% CI 4.7-6.9), however neither was significantly different from favorable intermediate risk men (5.9). There was no significant difference in treatment free survival between the three risk groups. At diagnosis, the three-year risk for pathologic grade progression (24%, 95% CI 21-27%) and progression to treatment (22%, 95% CI 20-25%) were similar. However, with increasing time of event-free AS, the conditional probability of pathologic grade progression increased, while that of progression to treatment decreased. Conclusions: Our results demonstrate that despite a mild increase in pathologic progression free survival in very low risk men, there was no clear difference in overall treatment free survival between very low, low, and select favorable intermediate NCCN risk men. Further, with increased time spent on AS, despite elevated rates of pathologic progression, patient progression to treatment decreased. This trend may be indicative of changes in goals of care as men with PCa age and should be closely monitored during AS.

Resectable Colonic Carcinoma—A Five Year Experience

1986 ◽  
Vol 31 (2) ◽  
pp. 90-93 ◽  
Author(s):  
Bashir ur Rehman ◽  
Abdul-Amir-Al-Dawood ◽  
A. Busuttil ◽  
W.P. Small
Keyword(s):  
High Risk ◽  
Active Surveillance ◽  
Clinical Characteristics ◽  
Risk Groups ◽  
Colonic Carcinoma ◽  
Minimum Length ◽  
Pathological Features ◽  
Carcinoma Of The Colon ◽  
Mode Of Presentation

Clinical characteristics, mode of presentation and pathological features of resectable carcinoma of the colon have been studied in 224 cases presenting between January 1971 and December 1975. Minimum length of follow-up is five years and is complete. Forty-three per cent of patients survived five years or more, only 23 per cent of tumours being early in histological terms. The conventional high risk groups contributed little to the total and their active surveillance will not significantly improve the overall statistics.

scholarly journals Prostate volume effect on Gleason score upgrading in active surveillance appropriate patients

2019 ◽  
Vol 91 (2) ◽  
Author(s):  
Emre Çamur ◽  
Alper Coşkun ◽  
Ӧvünç Kavukoğlu ◽  
Utku Can ◽  
Önder Kara ◽  
...  
Keyword(s):  
Active Surveillance ◽  
Gleason Score ◽  
Prostate Volume ◽  
Risk Groups ◽  
Volume Effect ◽  
P Value ◽  
Gleason Grade ◽  
Invasive Treatment ◽  
Surgical Specimen ◽  
The Relationship

Introduction: Gleason Score (GS) upgrading rates in the literature are reported to be around 33-45%. The relationship between prostate volume and GS upgrading should be defined, aiming to reduce upgrading rates in patients with low risk groups who are eligible for active surveillance (AS) or minimally invasive treatment, by varying biopsy cores, or lengths of cores according to prostate volumes. In this regard, the aim of our study was to establish the relationship between prostate volume and GS upgrading. Materials and methods: We retrospectively analyzed the medical records of 78 patients, who were appropriate for AS between 2011-2016 at our hospital. Inclusion criteria were patient age under 65 years, PSA level under 10 ng/ml, GS (3 + 3) or (3 + 4), and 3 or less positive cores, clinical stages ≤ T2. GS increase in radical prostatectomy specimen was considered as 'upgrading' and in addition, score reported by biopsy as 3 + 4 but in surgical specimen as 4 + 3 were also considered as 'upgrading'. The effect of prostate volume on Gleason grade upgrading was examined by calculating upgrading rates separately for patients with prostate volume 30 ml or less, those with 30 to 60 ml, and those over 60 ml. Results: As a result of the analysis of the data, upgrading was seen in 35 (44.8%) of 78 patients included in the study. In the cohort mean prostate volume was 49.8 (± 26.3) ml. Twenty-two patients (28.2%) had prostate volume 30 ml or less, 34 (43.6%) 30 to 60 ml, and 22 (28.2%) 60 ml or more. The patients were divided into two groups as those with and without GS upgrading. Between the groups prostate volume and prostate volume range (0-30/31-60/> 60) were not significantly different (p value > 0.05). Conclusions: Gleason grade upgrading causes patients to be classified in a lower risk group than they actually are, and may lead to inappropriate treatment. This condition has a direct effect on the decision of active surveillance. Therefore, it is important to define the factors that can predict GS upgrading in active surveillance appropriate patients. In this study, we found that prostate volume has no significant effect on upgrading in active surveillance appropriate patients.

scholarly journals Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends Across Risk Groups in the United States, 2010-2015

JAMA ◽  
2019 ◽  
Vol 321 (7) ◽  
pp. 704 ◽  
Author(s):  
Brandon A. Mahal ◽  
Santino Butler ◽  
Idalid Franco ◽  
Daniel E. Spratt ◽  
Timothy R. Rebbeck ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
United States ◽  
Active Surveillance ◽  
Watchful Waiting ◽  
Risk Groups ◽  
The United States ◽  
Low Risk ◽  
Risk Prostate Cancer ◽  
Low Risk Prostate Cancer

scholarly journals Active Surveillance of Asymptomatic, Presymptomatic, and Oligosymptomatic SARS-CoV-2-Infected Individuals in Communities Inhabiting Closed or Semi-closed Institutions

2021 ◽  
Vol 8 ◽  
Author(s):  
Nicolás Ambrosis ◽  
Pablo Martin Aispuro ◽  
Keila Belhart ◽  
Daniela Bottero ◽  
Renée Leonor Crisp ◽  
...  
Keyword(s):  
Residential Care ◽  
Active Surveillance ◽  
Buenos Aires ◽  
Close Contact ◽  
Risk Groups ◽  
Clinical Samples ◽  
Special Importance ◽  
Pooling Strategy ◽  
Two Stages ◽  
Dissemination Rate

Background: The high COVID-19 dissemination rate demands active surveillance to identify asymptomatic, presymptomatic, and oligosymptomatic (APO) SARS-CoV-2-infected individuals. This is of special importance in communities inhabiting closed or semi-closed institutions such as residential care homes, prisons, neuropsychiatric hospitals, etc., where risk people are in close contact. Thus, a pooling approach—where samples are mixed and tested as single pools—is an attractive strategy to rapidly detect APO-infected in these epidemiological scenarios.Materials and Methods: This study was done at different pandemic periods between May 28 and August 31 2020 in 153 closed or semi-closed institutions in the Province of Buenos Aires (Argentina). We setup pooling strategy in two stages: first a pool-testing followed by selective individual-testing according to pool results. Samples included in negative pools were presumed as negative, while samples from positive pools were re-tested individually for positives identification.Results: Sensitivity in 5-sample or 10-sample pools was adequate since only 2 Ct values were increased with regard to single tests on average. Concordance between 5-sample or 10-sample pools and individual-testing was 100% in the Ct ≤ 36. We tested 4,936 APO clinical samples in 822 pools, requiring 86–50% fewer tests in low-to-moderate prevalence settings compared to individual testing.Conclusions: By this strategy we detected three COVID-19 outbreaks at early stages in these institutions, helping to their containment and increasing the likelihood of saving lives in such places where risk groups are concentrated.

Sign in / Sign up

Export Citation Format

Share Document